This therapeutic concept targets trained innate immunity in brain microglia — the phenomenon whereby prior inflammatory exposures (infection, trauma, metabolic stress) cause microglia to undergo long-lasting epigenetic reprogramming that primes them toward a hyper-inflammatory, neurotoxic state. Rather than broadly suppressing microglia (which risks impairing essential surveillance functions), this approach aims to selectively reset trained immune programs to restore homeostatic microglial identity while preserving beneficial innate immune responses.
The trained immunity program involves metabolic rewiring (succinate accumulation, glycolytic shift), histone modification at pro-inflammatory gene loci (H3K4me3, H3K27ac), and persistent NF-κB and AP-1 activation that outlasts the initial trigger. This creates a self-reinforcing loop where low-level chronic inflammation perpetuates the trained state, contributing to progressive neurotoxicity in Alzheimer's disease (AD), Parkinson's disease (PD), ALS, and aging.
- Well-established in immunology: Trained immunity was first described in 2011 as a beta-glucan-induced epigenetic reprogramming of monocytes that enhanced their inflammatory response to secondary challenges. The concept has since been extended to microglia[@wendeln2018; @beyk2023].
- Directly implicated in neurodegeneration: Microglia in AD, PD, and ALS show a distinct transcriptional signature distinct from homeostatic microglia[@butovsky2014; @kerenshaul2017; @holtm2018] — characterized by increased expression of inflammatory genes (TNF, IL-1β, CCL2) and suppressed homeostatic genes (CX3CR1, P2RY12, TMEM119). This "disease-associated microglia" (DAM) or "microglia neurodegenerative phenotype" (MGnD) signature reflects trained immunity-like reprogramming.
- Key mechanism: Aβ oligomers, alpha-synuclein fibrils, and TDP-43 aggregates act as training agents — binding to TLRs, NLRP3 inflammasome, and TREM2 to drive metabolic and epigenetic reprogramming toward the MGnD state[@butovsky2014; @kerenshaul2017].
- Metabolic rewiring is targetable: Trained microglia shift toward glycolysis (via HIF-1α stabilization) and succinate accumulation. PHD activators or SDH inhibitors can reverse this metabolic state.
- Epigenetic targeting is feasible: BET protein inhibitors (e.g., JQ1, ABBV-744) suppress microglial activation by blocking BRD4 recruitment to inflammatory gene promoters.
- Cognitive evidence: Blocking trained immunity reduces amyloid plaque burden and rescues cognitive deficits in 5xFAD mice[@schwartz2021; @beyk2023].
- HIF-1α stabilization: PHD activators or SDH inhibitors to reduce succinate-driven HIF-1α-IL-1β loop
- Glycolysis inhibition: 2-deoxyglucose (2-DG) or glucose transporter inhibitors blunt the metabolic fueling of microglial activation
- BET protein inhibition: BRD4 inhibitors (JQ1, ABBV-744, OXP9) block BRD4 recruitment to inflammatory gene loci
- HDAC inhibitor therapy: Class I/II HDAC inhibitors (e.g., valproic acid, entinostat) suppress pro-inflammatory gene expression
- LSD1/KDM1A inhibition: LSD1 inhibitors (e.g., SP2509) promote M2-like microglial polarization
- EZH2 inhibition: EZH2 inhibitors (tazemetostat, GSK126) derepress homeostatic microglial genes
- TREM2 agonism: Partial TREM2 agonism favoring homeostatic signaling over MGnD
- CX3CR1 agonism: CX3CL1 fractalkine agonists reactivate the CX3CR1 signaling axis
- P2RY12/P2RY13 restoration: P2RY12 agonists restore homeostatic surveillance function
The therapeutic approach involves a multi-pronged reset strategy:
- Metabolic normalization: PHD activators or SDH inhibitors to reduce HIF-1α-driven glycolytic reprogramming
- Epigenetic reprogramming reversal: BET inhibitors (ABBV-744 or OXP9) to block BRD4 recruitment; HDAC activators or LSD1 inhibitors for anti-inflammatory gene expression; EZH2 inhibitors to derepress homeostatic genes (TMEM119, CX3CR1, P2RY12)
- Homeostatic receptor activation: CX3CL1 fractalkine agonists; partial TREM2 agonism
- Synergistic combination: Combine trained immunity reset with proteostasis enhancers, circadian entrainment, and NAD+ boosters
| Disease |
Score (1-10) |
Rationale |
| Alzheimer's Disease |
9 |
Aβ oligomers act as training agents; MGnD microglia drive amyloid plaque pathology; strong pre-clinical BET inhibitor evidence |
| Parkinson's Disease |
9 |
Alpha-synuclein fibrils trigger trained immunity; SNpc dopamine neurons vulnerable to microglial-mediated inflammation |
| ALS/FTD |
8 |
TDP-43 aggregates and C9orf72 DPR proteins drive microglial training; BET inhibition reduces motor neuron loss in SOD1 mice |
| Aging |
9 |
Normal aging causes microglial priming and trained immunity accumulation; "inflammaging" drives cognitive decline |
| FTD |
7 |
TDP-43 and tau pathology drive microglial training; GRN mutations cause excessive microglial activation |
| PSP/CBS |
6 |
4R-tau pathology triggers microglial activation; brainstem regions show heightened microglial density |
| MSA |
5 |
Alpha-synuclein in oligodendrocytes triggers microglial training |
Total Score: 77/100
- Novelty (8/10): Distinct from TREM2-LXR microglia state editing and CX3CR1 agonism — addresses long-lasting epigenetic reprogramming from prior exposures
- Mechanistic Rationale (9/10): Well-established in immunology (2011 discovery), extended to microglia (2018-2022), directly linked to neurodegeneration through DAM/MGnD signatures
- Root-Cause Coverage (8/10): Addresses upstream mechanism — prior inflammatory exposures creating self-reinforcing microglial reprogramming
- Delivery Feasibility (7/10): BET inhibitors, HDAC inhibitors, and metabolic modulators cross the BBB; small molecule approach feasible
- Safety Plausibility (7/10): Epigenetic modulators carry risks; microglial-selective targeting via nano-delivery systems and intermittent dosing mitigate risks
- Combinability (9/10): Highly synergistic with TREM2-LXR editing, autophagy inducers, circadian entrainment, NAD+ boosters
- Biomarker Availability (7/10): CSF IL-1β, TNF-α, IL-6; TSPO-PET for target engagement; single-cell RNA-seq of microglia for DAM/MGnD signature
- De-risking Path (7/10): Pre-clinical models available; BET inhibitors in clinical trials for oncology; HDAC inhibitors in clinical use
- Multi-disease Potential (10/10): Relevant across AD, PD, ALS, FTD, aging, and multiple rare tauopathies
- Patient Impact (8/10): Microglial neuroinflammation drives symptom progression; resetting trained immunity could slow progression and enhance other therapies
- Screen BET inhibitors, HDAC inhibitors, and metabolic modulators in 5xFAD mice for trained immunity reversal
- Validate epigenetic markers in trained microglia from AD patient iPSC-derived microglia
- Test combination with TREM2 agonism and autophagy inducers
- ABBV-744 or next-generation BET inhibitor for Phase 1a safety (healthy volunteers, elderly cohort)
- Biomarker validation: CSF cytokines, TSPO-PET, single-cell RNA-seq from blood monocytes
- Phase 1b/2a in early AD patients with microglial activation biomarker enrichment